The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

Cancer Policy

Trump cuts disrupted 383 clinical trials, affecting 74,000 trial participants

NIH employee placed on leave after openly criticizing Trump

Natalie Phelps, whose clinical trial was delayed due to RIFs, dies of colon cancer

Makary, Prasad describe FDA’s new “plausible mechanism pathway” to get bespoke therapies to market sans RCT

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

Trump administration and Cornell reach agreement to restore federal research funding

Clinical Roundup

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

One in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, KFF poll finds

Largest study on infant-type hemispheric glioma reports factors to guide treatment approaches

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

UAMS study finds digital barriers may limit rural cancer survivors from participating in research

In The Clinic
Regulatory News

FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

Trials & Tribulations
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account